In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery.
Nowhere is this more apparent than in the world of orphan drugs and, in particular, the emerging technology known as cell and gene therapy. Using gene therapy as a specific example, this white paper will discuss many of the high-touch services that can help enhance patient outcomes such as patient safety, access, adherence, quality-of-life, and effectiveness. By focusing on high touch services that can help enhance patient outcomes, biopharma and life sciences companies can overcome the market access challenges faced by orphan drugs.
Download this whitepaper to see how McKesson is helping enhance patient outcomes.
Remember my details
Privacy statement »
Manage your email preferences »
You will be emailed the document as an attachment (243Kb in size)